Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
Date
2020Author
Zhu, Zhen
Lu, Zhaohui
Xu, Tianmin
Chen, Cong
Yang, Gang
Zha, Tao
Lu, Jianchun
Xue, Yuan
Metadata
Show full item record
Documentos PDF
Abstract
Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were
divided into two groups: including lopinavir/ritonavir group (34 cases) and arbidol group (16 cases).
Lopinavir/ritonavir group received 400 mg/100mg of Lopinavir/ritonavir, twice a day for a week, while
the arbidol group was given 0.2 g arbidol, three times a day. Data from these patients were retrospectively analyzed. The cycle threshold values of open reading frame 1ab and nucleocapsid genes by RTPCR assay were monitored during antiviral therapy. None of the patients developed severe pneumonia
or ARDS. There was no difference in fever duration between the two groups (P=0.61). On day 14 after
the admission, no viral load was detected in arbidol group, but the viral load was found in 15(44.1%)
patients treated with lopinavir/ritonavir. Patients in the arbidol group had a shorter duration of positive
RNA test compared to those in the lopinavir/ritonavir group (P<0.01). Moreover, no apparent side effects
were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to
lopinavir/ritonavir in treating COVID-19.
Link to resource
https://doi.org/10.1016/j.jinf.2020.03.060Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.